A novel androstenedione derivative induces ROS-mediated autophagy and attenuates drug resistance in osteosarcoma by inhibiting macrophage migration inhibitory factor (MIF)

Cell Death and Disease

Volumn 5, Issue 8, 2014, Pages

  Liu, Y ^a   Zhao, L ^a,b   Ju, Y ^a   Li, W ^a   Zhang, M ^a   Jiao, Y ^a   Zhang, J ^a   Wang, S ^a   Wang, Y ^a   Zhao, M ^a   Zhang, B ^a   Zhao, Y ^a  

^a SHANDONG UNIVERSITY   (China)

^b Central Hospital of TaiAN   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3,4-DIHYDROXY-9,10-SECOANDROSTA-1,3,5,7-TETRAENE-9,17-DIONE; 3-METHYLADENINE; ACETYLCYSTEINE; ADENINE; ANDROSTENEDIONE; HIGH MOBILITY GROUP B1 PROTEIN; MACROPHAGE MIGRATION INHIBITION FACTOR; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; SECOSTEROID; SMALL INTERFERING RNA;

ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; AUTOPHAGY; BONE TUMOR; CHEMISTRY; DOWN REGULATION; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENE TRANSLOCATION; GENETICS; HUMAN; METABOLISM; OSTEOSARCOMA; PATHOLOGY; RNA INTERFERENCE; SYNTHESIS; TUMOR CELL LINE;

ACETYLCYSTEINE; ADENINE; ANDROSTENEDIONE; AUTOPHAGY; BONE NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGB1 PROTEIN; HUMANS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; OSTEOSARCOMA; PROTO-ONCOGENE PROTEINS C-BCL-2; REACTIVE OXYGEN SPECIES; RNA INTERFERENCE; RNA, SMALL INTERFERING; SECOSTEROIDS; TRANSLOCATION, GENETIC;

EID: 84906878287     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.300     Document Type: Article

References (54)

1. Endo-Munoz L, Cumming A, Sommerville S, Dickinson I, Saunders NA. Osteosarcoma is characterised by reduced expression of markers of osteoclastogenesis and antigen presentation compared with normal bone. Br J Cancer 2010; 103: 73-81.
2. Park JY, Kim YW, Park YK. Nrf2 expression is associated with poor outcome in osteosarcoma. Pathology 2012; 44: 617-621.
3. Endo-Munoz L, Cumming A, Sommerville S, Dickinson I, Saunders NA. Osteosarcoma is characterised by reduced expression of markers of osteoclastogenesisand antigenpresentation compared with normal bone. Br J Cancer 2010; 103: 73-81.
4. Moriceau G, Roelofs AJ, Brion R, Redini F, Ebetion FH, Rogers MJ et al. Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth. Cancer 2012; 118: 750-760.
5. Rosen G, Murphy ML, Huvos AG, Gutierrez M, Marcove RC. Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer 1976; 37: 1-11.
6. Huang J, Ni J, Liu K, Yu Y, Xie M, Kang R et al. HMGB1 promotes drug resistance in osteosarcoma. Cancer Res 2012; 72: 230-238.
7. Posthumadeboer J, van Egmond PW, Helder MN, de Menezes RX, Cleton-Jansen AM, Beliën JA et al. Targeting JNK-interacting-protein-1 (JIP1) sensitises osteosarcoma to doxorubicin. Oncotarget 2012; 3: 1169-1181.
8. Zhao YZ, Dai DD, Lu CT, Chen LJ, Lin M, Shen XT et al. Epirubicin loaded with propylene glycol liposomes significantly overcomes multidrug resistance in breast cancer. Cancer Lett 2013; 330: 74-83.
9. Winiarska M, Bil J, Wilczek E, Wilczynski GM, Lekka M, Engelberts PJ et al. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med 2008; 5: e64.
10. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003; 3: 791-800.
11. Bach JP, Deuster O, Balzer-Geldsetzer M, Meyer B, Dodel R, Bacher M. The role of macrophage inhibitory factor in tumorigenesis and central nervous system tumors. Cancer 2009; 115: 2031-2040.
12. Bucala R, Donnelly SC. Macrophage migration inhibitory factor: a probable link between inflammation and cancer. Immunity 2007; 26: 281-285.
13. Nishihira J. Macrophage migration inhibitory factor (MIF): its essential role in the immune system and cell growth. J Interferon Cytokine Res 2000; 20: 751-762.
14. Bach JP, Rinn B, Meyer B, Dodel R, Bacher M. Role of MIF in inflammation and tumorigenesis. Oncology 2008; 75: 127-133.
15. Mitchell RA. Mechanisms and effectors of MIF-dependent promotion of tumourigenesis. Cell Signal 2004; 16: 13-19.
16. Ohta S, Misawa A, Fukaya R, Inoue S, Kanemura Y, Okano H et al. Macrophage migration inhibitory factor (MIF) promotes cell survival and proliferation of neural stem/progenitor cells. J Cell Sci 2012; 125(Pt 13): 3210-3220.
17. Madeira MF, Queiroz-Junior CM, Costa GM, Santos PC, Silveira EM, Garlet GP et al. MIF induces osteoclast differentiation and contributes to progression of periodontal disease in mice. Microbes Infect 2012; 14: 198-206.
18. Asare Y, Schmitt M, Bernhagen J. The vascular biology of macrophage migration inhibitory factor (MIF). Expression and effects in inflammation, atherogenesis and angiogenesis. Thromb Haemost 2013; 109: 391-398.
19. Lee CY, Su MJ, Huang CY, Chen MY, Hsu HC, Lin CY et al. Macrophage migration inhibitory factor increases cell motility and up-regulates avb3 integrin in human chondrosarcoma cells. J Cell Biochem 2012; 113: 1590-1598.
20. Dessein AF, Stechly L, Jonckheere N, Dumont P, Monté D, Leteurtre E et al. Autocrine induction of invasive and metastatic phenotypes by the MIF-CXCR4 axis in drug-resistant human colon cancer cells. Cancer Res 2010; 70: 4644-4654.
21. Chen YC, Zhang XW, Niu XH, Xin DQ, Zhao WP, Na YQ et al. Macrophage migration inhibitory factor is a direct target of HBP1-mediated transcriptional repression that is overexpressed in prostate cancer. Oncogene 2010; 29: 3067-3078.
22. Bacher M, Schrader J, Thompson N, Kuschela K, Gemsa D, Waeber G et al. Up-regulation of macrophage migration inhibitory factor gene and protein expression in glial tumor cells during hypoxic and hypoglycemic stress indicates a critical role for angiogenesis inglioblastoma multiforme. Am J Pathol 2003; 162: 11-17.
23. Wu MY, Fu J, Xu J, O'Malley BW, Wu RC. Steroid receptor coactivator 3 regulates autophagy in breast cancer cells through macrophage migration inhibitory factor. Cell Res 2012; 22: 1003-1021.
24. Choudhary S, Hegde P, Pruitt JR, Sielecki TM, Choudhary D, Scarpato K et al. Macrophage migratory inhibitory factor promotes bladder cancer progression via increasing proliferation and angiogenesis. Carcinogenesis 2013; 34: 2891-2899.
25. He XX, Chen K, Yang J, Li XY, Gan HY, Liu CY et al. Macrophage migration inhibitory factor promotes colorectal cancer. Mol Med 2009; 15: 1-10.
26. Han I, Lee MR, Nam KW, Oh JH, Moon KC, Kim HS. Expression of macrophage migration inhibitory factor relates to survival in high-gradeosteosarcoma. Clin Orthop Relat Res 2008; 466: 2107-2113.
27. Cates JM, Friedman DB, Seeley EH, Dupont WD, Schwartz HS, Holt GE et al. Proteomic analysis of osteogenic sarcoma: association of tumour necrosis factor with poor prognosis. Int J Exp Pathol 2010; 91: 335-349.
28. Sih CJ, Lee SS, Tsong YY, Wang KC. Mechanisms of steroid oxidation by microorganisms. 8. 3, 4-Dihydroxy-9,10-secoandrosta-1,3,5(10)-triene-9,17-dione, an intermediate in the microbiological degradation of ring A of androst-4-ene-3,17-dione. J Biol Chem 1966; 241: 540-550.
29. Lin Y, Song X, Fu J, Lin J, Qu Y. Microbial transformation of androst-4-ene-3, 17-dione by Bordetella sp. B4 CGMCC 2229. J Chem Technol Biotechnol 2009; 84: 789-793.
30. Cheng P, Ni Z, Dai X, Wang B, Ding W, Rae Smith A et al. The novel BH-3 mimetic apogossypolone induces Beclin-1-and ROS-mediated autophagy in humanhepatocellular carcinoma cells. Cell Death Dis 2013; 4: e489.
31. Huang J, Liu K, Yu Y, Xie M, Kang R, Vernon P et al. Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcoma. Autophagy 2012; 8: 275-277.
32. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 2000; 19: 5720-5728.
33. Low IC, Kang J, Pervaiz S. Bcl-2: a prime regulator of mitochondrial redox metabolism in cancer cells. Antioxid Redox Signal 2011; 15: 2975-2987.
34. Tang D, Kang R, Livesey KM, Cheh CW, Farkas A, Loughran P et al. Endogenous HMGB1 regulates autophagy. J Cell Biol 2010; 190: 881-892.
35. Xu X, Wang B, Ye C, Yao C, Lin Y, Huang X et al. Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer. Cancer Lett 2008; 261: 147-157.
36. Hira E, Ono T, Dhar DK, El-Assal ON, Hishikawa Y, Yamanoi A et al. Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma. Cancer 2005; 103: 588-598.
37. Meyer-Siegler KL, Iczkowski KA, Leng L, Bucala R, Vera PL. Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. J Immunol 2006; 177: 8730-8739.
38. Winner M, Meier J, Zierow S, Rendon BE, Crichlow GV, Riggs R et al. A novel, macrophage migration inhibitory factor suicide substrate inhibits motility and growth of lung cancer cells. Cancer Res 2008; 68: 7253-7257.
39. Harding G, Mak YT, Evans B, Cheung J, MacDonald D, Hampson G. The effects of dexamethasone and dehydroepiandrosterone (DHEA) on cytokines and receptor expression in a human osteoblastic cell line: potential steroid-sparing role for DHEA. Cytokine 2006; 36: 57-68.
40. Balow JE, Rosenthal AS. Glucocorticoid suppression of macrophage migration inhibitory factor. J Exp Med 1973; 137: 1031-1041.
41. Schrader J, Deuster O, Rinn B, Schulz M, Kautz A, Dodel R et al. Restoration of contact inhibition in human glioblastoma cell lines after MIF knockdown. BMC Cancer 2009; 9: 464.
42. Rendon BE, Roger T, Teneng I, Zhao M, Al-Abed Y, Calandra T et al. Regulation of human lung adenocarcinoma cell migration and invasion by macrophage migration inhibitory factor. J Biol Chem 2007; 282: 29910-29918.
43. Kim JY, Kwok SK, Hur KH, Kim HJ, Kim NS, Yoo SA et al. Up-regulated macrophage migration inhibitory factor protects apoptosis of dermal fibroblasts in patients with systemic sclerosis. Clin Exp Immunol 2008; 152: 328-335.
44. Dunyaporn T, Weiqin L, Marcia AO, Nilsa R, Peng H. Redox Regulation of Cell Survival. Antioxid Redox Signal 2008; 10: 1343-1374.
45. Macus Tien K. Redox Regulation of Multidrug Resistance in Cancer Chemotherapy: Molecular Mechanisms and Therapeutic Opportunities. Antioxid Redox Signal 2009; 11: 99-133.
46. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature 2008; 451: 1069-1075.
47. Tang D, Kang R, Cheh CW, Livesey KM, Liang X, Schapiro NE et al. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene 2010; 29: 5299-5310.
48. Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N et al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 2005; 122: 927-939.
49. Luo S, Rubinsztein DC. Apoptosis blocks Beclin 1-dependent autophagosome synthesis: an effect rescued by Bcl-xL. Cell Death Differ 2010; 17: 268-277.
50. Liu L, Yang M, Kang R, Wang Z, Zhao Y, Yu Y et al. HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia 2011; 25: 23-31.
51. Tang D, Loze MT, Zeh HJ, Kang R. The redox protein HMGB1 regulates cell death and survival in cancer treatment. Autophagy 2010; 6: 1181-1183.
52. Gnanasekar M, Kalyanasundaram R, Zheng G, Chen A, Bosland MC, Kajdacsy-Balla A. HMGB1: A Promising Therapeutic Target for Prostate Cancer. Prostate Cancer 2013 2013 157103.
53. Lin Y, Liu J, Hu Y, Song X, Zhao Y. An antioxidant exopolysaccharide devoid of pro-oxidant activity produced by the soil bacterium Bordetella sp. B4. Bioresour Technol 2012; 124: 245-251.
54. 13 haploinsufficiency. J Biol Chem 2009; 284: 27409-27415.